The United States Preventive Services Task Force (USPSTF) released updated guidelines in 2009 recommending aspirin to prevent myocardial infarction among at-risk men and stroke among at-risk women.
Our aim was to examine clinician aspirin recommendation among eligible persons based on cardiovascular risk scores and USPSTF cutoffs.
We used across-sectional analysis of a current nationally representative sample.
Participants were aged 40 years and older, and in the National Health and Nutrition Examination Survey (NHANES) (2011–2012).
We determined aspirin eligibility for cardiovascular disease (CVD) prevention for each participant based on reported and assessed cardiovascular risk factors. We assessed men’s risk using a published coronary heart disease risk calculator based on Framingham equations, and used a similar calculator for stroke to assess risk for women. We applied the USPSTF risk cutoffs for sex and age that account for offsetting risk for gastrointestinal hemorrhage. We assessed clinician recommendation for aspirin based on participant report.
Among men 45–79 years and women 55–79 years, 87 % of men and 16 % of women were potentially eligible for primary CVD aspirin prevention. Clinician recommendation rates for aspirin among those eligible were low, 34 % for men and 42 % for women. Rates were highest among diabetics (63 %), those 65 to 79 years (52 %) or those in poor health (44 %). In contrast, aspirin recommendation rates were 76 % for CVD secondary prevention. After accounting for patient factors, particularly age, eligibility for aspirin prevention was not significantly associated with receiving a clinician’s recommendation for aspirin (AOR 0.99 %; CI 0.7–1.4).
Despite an “A recommendation” from the USPSTF for aspirin for primary prevention of CVD, the majority of men and women potentially eligible for aspirin did not recall a clinical recommendation from their clinician.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Aspirin for the prevention of cardiovascular disease: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2009;150:396–404
Force USPST. Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med. 2002;136:157–160.
Goldstein LB, Bonito AJ, Matchar DB, Duncan PW, DeFriese GH, Oddone EZ, Paul JE, Akin DR, Samsa GP. Us national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices. Stroke. 1995;26:1607–1615.
Mosca L, Linfante AH, Benjamin EJ, Berra K, Hayes SN, Walsh BW, Fabunmi RP, Kwan J, Mills T, Simpson SL. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499–510.
Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the united states: Results of a national survey. Am J Prev Med. 2007;32:403–407.
George MG, Tong X, Sonnenfeld N, Hong Y. Recommended use of aspirin and other antiplatelet medications among adults--national ambulatory medical care survey and national hospital ambulatory medical care survey, united states, 2005–2008. MMWR. 2012;61:11–18.
Rivera CM, Song J, Copeland L, Buirge C, Ory M, McNeal CJ. Underuse of aspirin for primary and secondary prevention of cardiovascular disease events in women. J Wom Health. 2012;21:379–387.
Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among u.S. Adults behavioral risk factor surveillance system. Am J Prev Med. 2006;30:74–77.
Shires DA, Stange KC, Divine G, Ratliff S, Vashi R, Tai-Seale M, Lafata JE. Prioritization of evidence-based preventive health services during periodic health examinations. Am J Prev Med. 2012;42:164–173.
Siller-Matula JM. Hemorrhagic complications associated with aspirin: An underestimated hazard in clinical practice? JAMA. 2012;307:2318–2320.
Shillinglaw B, Viera AJ, Edwards T, Simpson R, Sheridan SL. Use of global coronary heart disease risk assessment in practice: A cross-sectional survey of a sample of u.S. Physicians. BMC Health Serv Res. 2012;12:20.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–1847.
D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: Adjustment for antihypertensive medication. The framingham study. Stroke. 1994;25:40–43.
Lousberg TR, Denham AM, Rasmussen JR. A comparison of clinical outcome studies among cholesterol-lowering agents. The Annals of pharmacotherapy. 2001;35:1599–1607.
Horne BD, May HT, Kfoury AG, Renlund DG, Muhlestein JB, Lappe DL, Rasmusson KD, Bunch TJ, Carlquist JF, Bair TL, Jensen KR, Ronnow BS, Anderson JL. The intermountain risk score (including the red cell distribution width) predicts heart failure and other morbidity endpoints. European journal of heart failure. 2010;12:1203–1213.
Horne BD, Muhlestein JB, Lappe DL, Brunisholz KD, May HT, Kfoury AG, Carlquist JF, Alharethi R, Budge D, Whisenant BK, Bunch TJ, Ronnow BS, Rasmusson KD, Bair TL, Jensen KR, Anderson JL. The intermountain risk score predicts incremental age-specific long-term survival and life expectancy. Translational research : the journal of laboratory and clinical medicine. 2011;158:307–314.
U.S. Department of Health and Human Services (DHHS) CfDCaPC, National Center for Health Statistics (NCHS). . National health and nutrition examination survey: Analytic guidelines, 1999–2010. Dhhs publication no. 2013–1361. Sept 2013
Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res. 2008;8:60
Pignone M, Phillips CJ, Elasy TA, Fernandez A. Physicians’ ability to predict the risk of coronary heart disease. BMC Health Serv Res. 2003;3:13.
Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ. 1995;310:975–978.
Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med. 1996;124:414–421.
Jaen CR, Stange KC, Nutting PA. Competing demands of primary care: A model for the delivery of clinical preventive services. J Fam Pract. 1994;38:166–171.
Yarnall KS, Pollak KI, Ostbye T, Krause KM, Michener JL. Primary care: Is there enough time for prevention? Am J Publ Health. 2003;93:635–641.
Shires D, Vashi R, Stange K, Divine G, Flocke S, Wunderlich T, Lafata JE. C-a4-04: The delivery of cancer and other preventive health services during periodic health examinations. Clin Med Res. 2011;9:147–147.
Litaker D, Flocke SA, Frolkis JP, Stange KC. Physicians’ attitudes and preventive care delivery: Insights from the dopc study. Prev Med. 2005;40:556–563.
Puhan MA, Singh S, Weiss CO, Varadhan R, Sharma R, Boyd CM. Evaluation of the benefits and harms of aspirin for primary prevention of cardiovascular events: A comparison of quantitative approaches. Rockville MD; 2013
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172:209–216.
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol. 2010;55:2878–2886.
Sutcliffe P, Connock M, Gurung T, Freeman K, Johnson S, Ngianga-Bakwin K, Grove A, Gurung B, Morrow S, Stranges S, Clarke A. Aspirin in primary prevention of cardiovascular disease and cancer: A systematic review of the balance of evidence from reviews of randomized trials. PloS one. 2013;8:e81970.
Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, Sandercock PA, Fox KA, Lowe GD, Murray GD. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: A randomized controlled trial. JAMA. 2010;303:841–848.
US Food and Drug Administration. Citizen’s Petition Denial Response [letter]. Docket No. FDA-1977-N-0018–2404; Rockville, MD: May 2, 2014. (FDA press release http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm390574.htm).
Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, McBride P, Eckel RH, Schwartz JS, Goldberg AC, Shero ST, Gordon D, Smith SC, Jr., Levy D, Watson K, Wilson PW. 2013 acc/aha guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013
Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decisions: A primary care physician survey. Arch Intern Med. 2010;170:470–477.
Persell SD, Lloyd-Jones DM, Friesema EM, Cooper AJ, Baker DW. Electronic health record-based patient identification and individualized mailed outreach for primary cardiovascular disease prevention: A cluster randomized trial. J Gen Intern Med. 2013;28:554–560.
Sequist TD, Gandhi TK, Karson AS, Fiskio JM, Bugbee D, Sperling M, Cook EF, Orav EJ, Fairchild DG, Bates DW. A randomized trial of electronic clinical reminders to improve quality of care for diabetes and coronary artery disease. Journal of the American Medical Informatics Association : JAMIA. 2005;12:431–437.
Hemens BJ, Holbrook A, Tonkin M, Mackay JA, Weise-Kelly L, Navarro T, Wilczynski NL, Haynes RB. Computerized clinical decision support systems for drug prescribing and management: A decision-maker-researcher partnership systematic review. Implementation science : IS. 2011;6:89.
Sheridan SL, Viera AJ, Krantz MJ, Ice CL, Steinman LE, Peters KE, Kopin LA, Lungelow D. The effect of giving global coronary risk information to adults: A systematic review. Arch Intern Med. 2010;170:230–239.
Ghorob A, Bodenheimer T. Sharing the care to improve access to primary care. New England Journal of Medicine. 2012;366:1955–1957.
Chen EH, Bodenheimer T. Improving population health through team-based panel management: Comment on “electronic medical record reminders and panel management to improve primary care of elderly patients”. Arch Intern Med. 2011;171:1558–1559.
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA. 2001;285:2370–2375.
Prineas RJ, Le A, Soliman EZ, Zhang ZM, Howard VJ, Ostchega Y, Howard G. United states national prevalence of electrocardiographic abnormalities in black and white middle-age (45- to 64-year) and older (>/=65-year) adults (from the reasons for geographic and racial differences in stroke study). The American journal of cardiology. 2012;109:1223–1228.
Sheridan SL, Harris RP, Woolf SH. Shared decision making about screening and chemoprevention. A suggested approach from the U.S. Preventive services task force. Am J Prev Med. 2004;26:56–66.
Politi MC, Wolin KY, Legare F. Implementing clinical practice guidelines about health promotion and disease prevention through shared decision making. J Gen Intern Med. 2013;28:838–844.
Horne BD, May HT, Muhlestein JB, Ronnow BS, Lappe DL, Renlund DG, Kfoury AG, Carlquist JF, Fisher PW, Pearson RR, Bair TL, Anderson JL. Exceptional mortality prediction by risk scores from common laboratory tests. Am J Med. 2009;122:550–558.
We acknowledge Carol Moulthroup for her assistance with the proofing and submission process.
Conflict of Interest
The authors declare they have no conflict of interest.
External and Internal Funding Sources
Rights and permissions
About this article
Cite this article
Fiscella, K., Winters, P.C., Mendoza, M. et al. Do Clinicians Recommend Aspirin to Patients for Primary Prevention of Cardiovascular Disease?. J GEN INTERN MED 30, 155–160 (2015). https://doi.org/10.1007/s11606-014-2985-8
- primary CVD prevention
- USPSTF guidelines